This specific ISBN edition is currently not available.View all copies of this ISBN edition:
The PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013 is the leading resource for statistics, trends, and proprietary market intelligence and analysis on the biopharmaceutical industry. Supported by thousands of graphs, illustrations, and analysis, the Sourcebook provides the latest market intelligence on every aspect of biopharmaceutical development from product discovery, to R&D performance and productivity, to time-to-market trends. With key analysis and contributions from leading consultancies and experts, the Sourcebook provides real-world data and analysis, including: * A record number of all-new metrics on drug development costs and complexity. * New proprietary analyses on US clinical trial starts, segmented by therapeutic category, as well as overall active clinical trials. * Emerging data on worldwide and company-specific R&D pipelines, strategies, and product launch trends. * New analyses on emerging trends in pharma and biotech licensing deals and other partnerships critical to industry's efforts. * Drug approval statistics compiled from FDA, EMEA, and other regulatory agencies. * New global R&D spending trends and other international R&D data from key markets. * International statistics on drug development output. * And much more! Plus, NEW in the 2012/2013 edition: * An all-new 2012 analysis on the current share of clinical trial spending by region for 2011. * All-new studies on the emerging clinical trial markets in India, China, Korea, Canada, and dozens of other key markets and regions. * All-new analyses and actual/projected metrics on the biosimilars market. * A series of new "dashboards" on costs by phase of development, R&D attrition rates, product development times, and other areas. * Forecasting models on biopharma sales, R&D spending, the pharma/biotech markets, and other meaningful industry metrics. The PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013 is a must-have resource for the drug development industry. It is an invaluable resource for executives and managers working in the pharma and biotech industries. The Sourcebook puts real-world data sets at your fingertips for presentations, reports, business development efforts, strategic meetings, and critical decision-making analyses.
"synopsis" may belong to another edition of this title.
This is an incredibly useful and reliable resource for anyone connected to the pharmaceutical and biotech industries: marketers, financial planners, investors, or researchers. --Judy Blaine, Librarian, ArQule, Inc., Business Information Alert
The PAREXEL Biopharmaceutical R&D Statistical Sourcebook is the industry's most complete source of statistics and other facts about drug development. It's hard to imagine how anyone could understand current trends in drug development without this book. --Norman M. Goldfarb, Managing Director, First Clinical Research, LLC
The PAREXEL Biopharmaceutical R&D Statistical Sourcebook is one of the most important sources for accurate industry and regulatory data, and for some tables, it is the only source. --Bert Spilker, President, Bert Spilker & Associates, LLC
"About this title" may belong to another edition of this title.
Book Description Parexel Intl Corp, 2012. Condition: New. book. Seller Inventory # M1882615972
Book Description Parexel Intl Corp, 2012. Hardcover. Condition: New. Never used!. Seller Inventory # P111882615972